U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C32H26N4O2
Molecular Weight 498.5756
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CONIVAPTAN

SMILES

Cc1nc2CCN(c3ccccc3-c2[nH]1)C(=O)c4ccc(cc4)NC(=O)c5ccccc5-c6ccccc6

InChI

InChIKey=IKENVDNFQMCRTR-UHFFFAOYSA-N
InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)

HIDE SMILES / InChI

Molecular Formula C32H26N4O2
Molecular Weight 498.5756
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21409494 | https://www.ncbi.nlm.nih.gov/pubmed/18926434

Conivaptan is an arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V1A and V2. The antidiuretic action of AVP is mediated through activation of the V2 receptor, which functions to regulate water and electrolyte balance at the level of the collecting ducts in the kidney. Conivaptan was approved in 2004 for hyponatremia caused by syndrome of inappropriate antidiuretic hormone. Conicaptan is being evaluated for reduce intracranial pressure in patients with traumatic brain injury, and as a treatment for heart failure.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Approved Use

VAPRISOL is a vasopressin receptor antagonist indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia.

Launch Date

1.13581438E12
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2681 ng/mL
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CONIVAPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
619 ng/mL
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CONIVAPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4813 ng × h/mL
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CONIVAPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.1 h
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CONIVAPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5 h
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CONIVAPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
40 mg/kg single, intravenous
dose: 40 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CONIVAPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 68.7 years (range: 35–90 years)
n = 27
Health Status: unhealthy
Condition: euvolemic hyponatremia | hypervolemic hyponatremia
Age Group: 68.7 years (range: 35–90 years)
Sex: M+F
Population Size: 27
Sources:
120 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 120 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Congestive heart failure
Age Group: adult
Sources:
Other AEs: Hypotension, Thirst...
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Disc. AE: Hypopituitarism, Infusion site reaction...
AEs leading to
discontinuation/dose reduction:
Hypopituitarism (0.2%)
Infusion site reaction (0.2%)
Infusion site phlebitis (1.6%)
Infusion related reaction (0.2%)
Sepsis NOS (0.2%)
Pneumonia NOS (0.2%)
Blood creatinine increased (0.2%)
Blood sodium increased (0.2%)
Blood urea increased (0.2%)
Heart rate increased (0.2%)
Hypernatremia (0.8%)
Epilepsy NOS (0.2%)
Agitation (0.2%)
Renal failure acute (0.2%)
Respiratory arrest (0.2%)
Respiratory failure (0.2%)
Cyanosis peripheral (0.2%)
Phlebitis NOS (0.2%)
Phlebitis superficial (0.2%)
Sources: Page: p. 64
12.5 mg single, intravenous
Dose: 12.5 mg
Route: intravenous
Route: single
Dose: 12.5 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 6
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Other AEs: Coagulopathy, Cardiac failure congestive...
Other AEs:
Coagulopathy (serious, 1 patient)
Cardiac failure congestive (serious, 2 patients)
Multi-organ failure (serious, 1 patient)
Hyponatraemia (serious, 1 patient)
Transient ischaemic attack (serious, 1 patient)
Renal failure (serious, 1 patient)
Respiratory distress (serious, 1 patient)
Hypocoagulable state (below serious, 1 patient)
Leukocytosis (below serious, 1 patient)
Arrhythmia ventricular (below serious, 1 patient)
Abdominal discomfort (below serious, 1 patient)
Abdominal distension (below serious, 2 patients)
Abnormal bowel sounds (below serious, 1 patient)
Constipation (below serious, 2 patients)
Nausea (below serious, 2 patients)
Fatigue (below serious, 1 patient)
Hypothermia (below serious, 1 patient)
Pain (below serious, 2 patients)
Procedural pain (below serious, 1 patient)
Breath sounds abnormal (below serious, 1 patient)
Chest X-ray abnormal (below serious, 1 patient)
Hypoalbuminaemia (below serious, 1 patient)
Hypomagnesaemia (below serious, 2 patients)
Hypophosphataemia (below serious, 1 patient)
Hypovolaemia (below serious, 1 patient)
Muscle spasms (below serious, 1 patient)
Headache (below serious, 1 patient)
Lethargy (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Dysuria (below serious, 1 patient)
Cough (below serious, 1 patient)
Postnasal drip (below serious, 1 patient)
Rales (below serious, 1 patient)
Pruritus (below serious, 1 patient)
Hypotension (below serious, 3 patients)
Sources:
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Other AEs: Cardiac failure congestive, Pneumonia...
Other AEs:
Cardiac failure congestive (serious, 1 patient)
Pneumonia (serious, 1 patient)
Respiratory acidosis (serious, 1 patient)
Coronary artery bypass (serious, 1 patient)
Hypotension (serious, 1 patient)
Dry eye (below serious, 1 patient)
Constipation (below serious, 2 patients)
Nausea (below serious, 1 patient)
Vomiting (below serious, 2 patients)
Chest pain (below serious, 1 patient)
Fatigue (below serious, 1 patient)
Oedema peripheral (below serious, 1 patient)
Bronchitis chronic (below serious, 1 patient)
Contusion (below serious, 1 patient)
Blood pressure decreased (below serious, 1 patient)
Cardiac murmur (below serious, 1 patient)
Carotid bruit (below serious, 1 patient)
Heart sounds abnormal (below serious, 1 patient)
Dehydration (below serious, 1 patient)
Hypernatraemia (below serious, 1 patient)
Hypokalaemia (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Headache (below serious, 1 patient)
Insomnia (below serious, 2 patients)
Psychotic disorder (below serious, 1 patient)
Haematuria (below serious, 1 patient)
Pruritus (below serious, 1 patient)
Haematoma (below serious, 1 patient)
Thrombophlebitis (below serious, 1 patient)
Sources:
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Other AEs: Atrial tachycardia, Urinary tract infection...
Other AEs:
Atrial tachycardia (serious, 1 patient)
Urinary tract infection (serious, 1 patient)
Encephalopathy hepatic (serious, 1 patient)
Atrial flutter (below serious, 1 patient)
Nausea (below serious, 1 patient)
Vomiting (below serious, 1 patient)
Polydipsia (below serious, 1 patient)
Back pain (below serious, 1 patient)
Productive cough (below serious, 1 patient)
Dry skin (below serious, 1 patient)
Phlebitis (below serious, 2 patients)
Sources:
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Other AEs: Cardiac arrest, Atrial flutter...
Other AEs:
Cardiac arrest (serious, 1 patient)
Atrial flutter (below serious, 1 patient)
Ventricular tachycardia (below serious, 1 patient)
Constipation (below serious, 1 patient)
Infusion site erythema (below serious, 3 patients)
Infusion site pain (below serious, 1 patient)
Pyrexia (below serious, 1 patient)
Heart rate increased (below serious, 1 patient)
Muscle spasms (below serious, 1 patient)
Pain in extremity (below serious, 1 patient)
Headache (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension
120 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 120 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Congestive heart failure
Age Group: adult
Sources:
Thirst
120 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 120 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Congestive heart failure
Age Group: adult
Sources:
Agitation 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Blood creatinine increased 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Blood sodium increased 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Blood urea increased 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Cyanosis peripheral 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Epilepsy NOS 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Heart rate increased 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Hypopituitarism 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Infusion related reaction 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Infusion site reaction 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Phlebitis NOS 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Phlebitis superficial 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Pneumonia NOS 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Renal failure acute 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Respiratory arrest 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Respiratory failure 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Sepsis NOS 0.2%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Hypernatremia 0.8%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Infusion site phlebitis 1.6%
Disc. AE
40 mg 1 times / day multiple, intravenous
Recommended
Dose: 40 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p. 64
unhealthy, adult
n = 445
Health Status: unhealthy
Age Group: adult
Population Size: 445
Sources: Page: p. 64
Dizziness below serious, 1 patient
12.5 mg single, intravenous
Dose: 12.5 mg
Route: intravenous
Route: single
Dose: 12.5 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 6
Sources:
Abdominal discomfort below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Abnormal bowel sounds below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Anxiety below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Arrhythmia ventricular below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Breath sounds abnormal below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Chest X-ray abnormal below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Cough below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Dysuria below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Fatigue below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Headache below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypoalbuminaemia below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypocoagulable state below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypophosphataemia below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypothermia below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypovolaemia below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Lethargy below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Leukocytosis below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Muscle spasms below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Postnasal drip below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Procedural pain below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Pruritus below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Rales below serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Abdominal distension below serious, 2 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Constipation below serious, 2 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypomagnesaemia below serious, 2 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Nausea below serious, 2 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Pain below serious, 2 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypotension below serious, 3 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Coagulopathy serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hyponatraemia serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Multi-organ failure serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Renal failure serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Respiratory distress serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Transient ischaemic attack serious, 1 patient
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Cardiac failure congestive serious, 2 patients
20 mg 1 times / day multiple, intravenous
Dose: 20 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Blood pressure decreased below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Bronchitis chronic below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Cardiac murmur below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Carotid bruit below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Chest pain below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Contusion below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Dehydration below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Dry eye below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Fatigue below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Haematoma below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Haematuria below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Headache below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Heart sounds abnormal below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypernatraemia below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypokalaemia below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Nausea below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Neck pain below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Oedema peripheral below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Pruritus below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Psychotic disorder below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Thrombophlebitis below serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Constipation below serious, 2 patients
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Insomnia below serious, 2 patients
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Vomiting below serious, 2 patients
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Cardiac failure congestive serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Coronary artery bypass serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Hypotension serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Pneumonia serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Respiratory acidosis serious, 1 patient
20 mg 2 times / day multiple, intravenous
Dose: 20 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Euvolemic or Hypervolemic Hyponatremia
Population Size: 20
Sources:
Atrial flutter below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Back pain below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Dry skin below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Nausea below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Polydipsia below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Productive cough below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Vomiting below serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Phlebitis below serious, 2 patients
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Atrial tachycardia serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Encephalopathy hepatic serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Urinary tract infection serious, 1 patient
22.5 mg single, intravenous
Dose: 22.5 mg
Route: intravenous
Route: single
Dose: 22.5 mg
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: Liver Cirrhosis
Population Size: 9
Sources:
Atrial flutter below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Constipation below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Headache below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Heart rate increased below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Infusion site pain below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Muscle spasms below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Pain in extremity below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Pyrexia below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Ventricular tachycardia below serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Infusion site erythema below serious, 3 patients
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Cardiac arrest serious, 1 patient
60 mg single, intravenous
Dose: 60 mg
Route: intravenous
Route: single
Dose: 60 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Condition: Acute Decompensated Heart Failure
Population Size: 6
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
strong [IC50 0.47 uM]
yes (co-administration study)
Comment: coadministration with midazolam or simvastatin significantly increased both CYP3A4 substrates
Page: 20, 48
weak [IC50 198.3 uM]
yes [IC50 12.6 uM]
yes [IC50 13.3 uM]
yes (co-administration study)
Comment: coadministration with warfarin increased warfarin WUC by 14% amd Cmax by 17%
Page: 10, 48
yes [IC50 19.2 uM]
yes
yes (co-administration study)
Comment: coadministration with digoxin resulted in increased Cmax by 79% and AUC by 43%
Page: 10, 21
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: ketoconazole increased conivaptan AUC 11-fold
Page: 38.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.
2002 Aug 23
Conivaptan (Yamanouchi).
2002 Jan
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
2003 Jul
Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
2003 Jun
Gateways to clinical trials.
2003 Nov
Vasopressin antagonists in heart failure.
2004 Dec
Gateways to clinical trials.
2004 Jul-Aug
Conivaptan Yamanouchi.
2005 Mar
Vasopressin antagonism: a future treatment option in heart failure.
2005 Mar
Vasopressin receptor antagonists in the management of acute heart failure.
2005 May
Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
2005 May 2
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
2006 Jan
Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
2006 Jun
Cardiac function and heart failure.
2006 Jun 6
AVP receptor antagonists as aquaretics: review and assessment of clinical data.
2006 Sep
Cerebral correlates of hyponatremia.
2007
Management of hyponatremia and clinical use of vasopressin antagonists.
2007 Feb
New drugs 07, part I.
2007 Feb
Conivaptan: a step forward in the treatment of hyponatremia?
2008 Apr
The management of ascites and hyponatremia in cirrhosis.
2008 Feb
[Etiology, diagnostics and therapy of hyponatremias].
2008 Jul 20
Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
2008 Oct
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.
2009 Jul
Hyponatremia: case vignettes.
2009 May
Patents

Sample Use Guides

In Vivo Use Guide
IV: 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2 to 4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium not rising sufficiently; total duration of therapy not to exceed 4 days. Note: If patient requires 40 mg/24 hours, may administer two consecutive 20 mg/100 mL premixed solutions over 24 hours (ie, 20 mg over 12 hours followed by 20 mg over 12 hours).
Route of Administration: Intravenous
Binding of conivaptan with recombinant human vasopressin V1a and V2 receptors was studied using [3H]-Arg-vasopressin as a radioligand. Conivaptan binds to V1a with Ki of 0.43 and to V2 receptor with Ki of 0.36 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 11:07:17 UTC 2021
Edited
by admin
on Sat Jun 26 11:07:17 UTC 2021
Record UNII
0NJ98Y462X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CONIVAPTAN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
(1,1'-BIPHENYL)-2-CARBOXAMIDE, N-(4-((4,5-DIHYDRO-2-METHYLIMIDAZO(4,5-D)(1)BENZAZEPIN-6(1H)-YL)CARBONYL)PHENYL)-
Systematic Name English
4''-((4,5-DIHYDRO-2-METHYLIMIDAZO(4,5-D)(1)BENZAZEPIN-6(1H)-YL)CARBONYL)-2-BIPHENYLCARBOXANILIDE
Common Name English
CONIVAPTAN [VANDF]
Common Name English
CONIVAPTAN [INN]
Common Name English
CONIVAPTAN [MI]
Common Name English
CONIVAPTAN [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000009945
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
WHO-ATC C03XA02
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
WHO-VATC QC03XA02
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
NDF-RT N0000178376
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
NCI_THESAURUS C2180
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
Code System Code Type Description
EPA CompTox
210101-16-9
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
EVMPD
SUB32706
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
DRUG CENTRAL
732
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
CAS
210101-16-9
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
MESH
C106389
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
WIKIPEDIA
CONIVAPTAN
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
RXCUI
302285
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY RxNorm
FDA UNII
0NJ98Y462X
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
IUPHAR
2203
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
INN
7947
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
MERCK INDEX
M3761
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1755
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
NCI_THESAURUS
C74428
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
PUBCHEM
151171
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
DRUG BANK
DB00872
Created by admin on Sat Jun 26 11:07:18 UTC 2021 , Edited by admin on Sat Jun 26 11:07:18 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
IC50
EXCRETED UNCHANGED
There was no quantitative assessment for conivaptan and its metabolites in fecal excretion.
AMOUNT EXCRETED
URINE
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC